Navigation Links
Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009
Date:10/27/2009

524,459 818,669 ------- ------- CASH AND CASH EQUIVALENTS, END OF PERIOD $1,453,814 $846,595 ========== ======== *As adjusted in accordance with the transition provisions of accounting for convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) and accounting for noncontrolling interests in consolidated financial statements. CEPHALON, INC. AND SUBSIDIARIES Reconciliation of Projected GAAP Basic Income per Common Share to Basic Adjusted Income Per Common Share Guidance (Unaudited) Twelve Months Twelve Months Ended Ended December 31, December 31, 2009 2010 ------------- ------------ Projected GAAP basic income per common share $4.69 - $4.79 $4.95 - $5.15 ===== ===== ===== ===== Amortization of current intangibles $1.34 - $1.34 $1.20 - $1.20 Accelerated depreciation adjustment- CIMA $0.09 - $0.09 $0.08 - $0.08 Accelerated depreciation adjustment- Mitry-Mory $0.18 - $0.18 $0.09 - $0.09 Research and development adjustments $0.05 - $0.05 $- - $- Selling, general and administrative adjustments $0.20 - $0.20 $- - $- Cost of goods sold adjustments $(0.09) - $(0.09) $- - $- Restructuring adjustments $0.07 - $0.07 $0.08 - $0.08 Acquired in-process research and development adj
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: ... Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... Novartis AG (NYSE: NVS ). Free research on ... . On Friday, December 12, 2014, the NASDAQ Composite ... lost 1.79%, to finish the day at 17,280.83, and the ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO and ... Quantum Materials Corp (OTCQB:QTMM), will be speaking at ... Materials (RCQM) on December 16th, 2014. The RCQM launch ... nanomaterials in attracting top faculty and students and by ... on research. "We have a long ...
(Date:12/15/2014)...  The Government of Ghana has endorsed ... (GBF) and Terumo BCT to respond to the emerging Ebola crisis ... long-term health system capacity to the citizens of Ghana ... Ebola Readiness and Resilience Initiative (GERRI) is a multi-agency effort designed ... the possible arrival of the Ebola epidemic , Provide new ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6
... , , , ... The rating agency Moody,s changed the outlook for ... , Moody,s gave as a ... the group,s business model. , , , ...
... INDIANAPOLIS , April 22 Today, WellPoint, Inc. (NYSE: ... article published this morning. , , ... Today,s Reuters story alleging that WellPoint employs a ... inaccurate and grossly misleading . The story incorrectly reports that WellPoint singles out ...
Cached Medicine Technology:Moody's Raised Outlook for Gerresheimer 2WellPoint's Reuters Response 2WellPoint's Reuters Response 3WellPoint's Reuters Response 4
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
(Date:12/17/2014)... Amy Norton HealthDay Reporter ... has long been believed to improve overall health, but a ... help the heart, a new review finds. In fact, ... as brisk walking, said lead researcher Paula Chu, a doctoral ... The review, of 37 clinical trials, found that people randomly ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s ... new study providing evidence on the impact of 100% ... , Sufficient enough evidence already exists showing a negative ... drinks, with the onset of tooth decay. One question ... as 100% fruit juice, meaning it is completely natural ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... N.J., Nov. 6 Osteotech, Inc.,(Nasdaq: OSTE ) ... to $25.7 million from third quarter 2006 revenue of ... 28% to $17.6 million for the three months ended ... from the same segments for the,third quarter of 2006. ...
... Thursday, November 8,2007, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC and MTAX: CTIC),management team will host ... quarter achievements and financial results. Conference Call ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... SOUTH SAN FRANCISCO, Calif., Nov. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and nine months ended September 30, 2007. For the ... $18.9,million, or $0.61 per share, compared to a net loss ... of 2006. Weighted average shares,outstanding for the third quarters of ...
... 6 - Elsevier Signs Agreement With ... major global healthcare company, Bayer,HealthCare AG, headquartered in ... Classic. Available in electronic format for,the first time, ... from 43 Excerpta Medica Abstract Journals published between ...
... TSX: COM, VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - Cardiome ... Bob Rieder, Chairman and,Chief Executive Officer, will present an ... Conference in New York at 1:20pm Eastern,Time (10:20am Pacific ... webcast of Mr. Rieder,s presentation can be accessed on,Cardiome,s ...
... StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: SSUR.OB) ... ("FDA"), through its Center for Devices and,Radiological Health, ... Amendments of 1988 ("CLIA") for an HIV 1/2 ... HIV 1/2 product,is marketed and distributed worldwide by ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Rigel Announces Third Quarter 2007 Financial Results 2Health News:Rigel Announces Third Quarter 2007 Financial Results 3Health News:Rigel Announces Third Quarter 2007 Financial Results 4Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 2Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 3Health News:Cardiome to Present at CIBC Conference 2Health News:Cardiome to Present at CIBC Conference 3Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches....
Medicine Products: